BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25231195)

  • 21. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
    Noori SF; Gangi A; Nelson ME; Choi M; Mirzadehgan P; Bonk AK; Mirocha J; Amersi F; Giuliano AE
    Ann Surg Oncol; 2014 Oct; 21(10):3324-9. PubMed ID: 25047471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
    Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls.
    Locke I; Kote-Jarai Z; Bancroft E; Bullock S; Jugurnauth S; Osin P; Nerurkar A; Izatt L; Pichert G; Gui GP; Eeles RA
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1399-402. PubMed ID: 16835343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.
    Wong ES; Shekar S; Chan CH; Hong LZ; Poon SY; Silla T; Lin C; Kumar V; Davila S; Voorhoeve M; Thike AA; Ho GH; Yap YS; Tan PH; Tan MH; Ang P; Lee AS
    PLoS One; 2015; 10(7):e0134408. PubMed ID: 26221963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients.
    Jouhadi H; Tazzite A; Azeddoug H; Naim A; Nadifi S; Benider A
    BMC Res Notes; 2016 Apr; 9():248. PubMed ID: 27129401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Gronwald J; Lynch HT; Eisen A; Neuhausen SL; Tung N; Ainsworth P; Weitzel JN; Pal T; Foulkes WD; Eng C; Singer CF; Senter L; Sun P; Lubinski J; Narod SA;
    Breast Cancer Res Treat; 2018 Sep; 171(2):421-426. PubMed ID: 29774471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PML protein expression in hereditary and sporadic breast cancer.
    Plevová P; Bouchal J; Fiurásková M; Foretová L; Navrátilová M; Zapletalová J; Curík R; Kubala O; Prokop J; Kolár Z
    Neoplasma; 2007; 54(4):263-8. PubMed ID: 17822314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
    Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
    Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
    Murakami W; Tozaki M; Nakamura S; Ide Y; Inuzuka M; Hirota Y; Murakami K; Takahama N; Ohgiya Y; Gokan T
    Breast Cancer; 2019 Sep; 26(5):552-561. PubMed ID: 30820924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
    Karp SE; Tonin PN; Bégin LR; Martinez JJ; Zhang JC; Pollak MN; Foulkes WD
    Cancer; 1997 Aug; 80(3):435-41. PubMed ID: 9241077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Gershman S; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; McLennan J; Eisen A; Foulkes WD; Rosen B; Sun P; Narod SA
    Br J Cancer; 2011 Apr; 104(9):1384-92. PubMed ID: 21487411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece.
    Triantafyllidou O; Vlachos IS; Apostolou P; Konstantopoulou I; Grivas A; Panopoulos C; Dimitrakakis C; Kassanos D; Loghis C; Bramis I; Vlahos N; Yannoukakos D; Fostira F
    J BUON; 2015; 20(4):978-84. PubMed ID: 26416046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
    Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
    Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
    Lee E; McKean-Cowdin R; Ma H; Spicer DV; Van Den Berg D; Bernstein L; Ursin G
    J Clin Oncol; 2011 Nov; 29(33):4373-80. PubMed ID: 22010008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.